News: Vectura Group Plc (VEC.L)

VEC.L on London Stock Exchange

78.50GBp
18 Dec 2009
Price Change (% chg)

-0.10p (-0.13%)
Prev Close
78.60p
Open
78.00p
Day's High
82.90p
Day's Low
76.40p
Volume
6,820,622
Avg. Vol
586,747
52-wk High
101.90p
52-wk Low
46.50p

view news for:
Select another date:

Wed, Dec 9 2009

UPDATE 1-Aggreko to enter FTSE 100, Rentokil to leave

LONDON, Dec 9 (Reuters) - Temporary power producer Aggreko will enter the FTSE 100 later this month, replacing pest control-to-parcel delivery firm Rentokil Initial after a quarterly review, index complier FTSE said on Wednesday.

Continue Reading

UPDATE 1-Novartis wins EU approval for lung drug

ZURICH, Dec 3 (Reuters) - Swiss drugmaker Novartis AG said on Thursday it had won Europan Union approval for use of its Onbrez Breezhaler to widen the bronchial passages of patients with chronic obstructive pulmonary disease (COPD).

UPDATE 2-Vectura eyes Boehringer generic, H1 beats forecast

* H1 revenue up 71 pct to 22.8 million pounds, beating view

FTSE seen opening 35-46 points lower

LONDON (Reuters) - FTSE 100 is seen opening 35-46 points lower on Friday according to financial bookmakers, extending losses from the previous session following weakness in Asia as worries about the global economy mounted after Dubai's debt problems emerged.

UK Stocks -- Factors to watch on Nov 27

LONDON, Nov 27 (Reuters) - Britain's FTSE 100 is seen opening 35-46 points lower on Friday according to financial bookmakers, extending losses from the previous session following weakness in Asia as worries about the global economy mounted after Dubai's debt problems emerged.

Novartis says drugs unit to outshine

NEW YORK (Reuters) - Novartis AG's drugs unit will continue to outgrow a sickly overall pharmaceuticals market, driven by new treatments for cancer, multiple sclerosis and lung disease, its divisional chief said on Monday.

UPDATE 2-Vectura must wait for Novartis lung drug payment

* Associated $7.5 mln milestone seen in next fiscal year

U.S. seeks more information on Novartis lung drug

ZURICH (Reuters) - U.S. regulators have asked for more information on dosing proposed for a drug from Novartis AG for "smoker's lung," or chronic obstructive pulmonary disease, the Swiss group said on Monday.

UPDATE 2-US seeks more information on Novartis lung drug

* Novartis to work with FDA to see if more trials needed

International Biotech waiting for market to retrace

LONDON (Reuters) - Small-cap biotechnology shares have become too expensive and are poised for a fall, said David Pinniger, a investment manager at International Biotechnology Trust.

Select another date:

Market Views

» More VEC.L Market Views

Press Releases

view news for: